Clinical trials: Vulvar Carcinoma
Low Anterior Resection Syndrome, Malignant Anal Neoplasm
Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
This phase II trial studies how well sacral nerve stimulation works in treating low anterior resection syndrome or fecal incontinence (the body's passage of stool without control) in patients with rectal cancer that has spread to…
- Conditions
- Low Anterior Resection Syndrome, Malignant Anal Neoplasm, Malignant Bladder Neoplasm, Malignant Cervical Neoplasm
- Trial name
- NCT04066894
- Testing
- Explantation, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
- Trial name
- NCT00082823
- Testing
- ziv-aflibercept
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Genital Neoplasms, Female
Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies
The purpose of this clinical trial is to evaluate the effectiveness and safety of oncolytic viruses H101 intra-tumor injection combined with or without radiotherapy in refractory or recurrent gynecological malignancies.
- Trial name
- NCT05051696
- Testing
- H101
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Liu Zi
Breast Carcinoma, Cervical Carcinoma
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
This phase II randomized trial studies how well bupropion hydrochloride works in improving sexual desire in women with breast or gynecological cancer.
- Conditions
- Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal
- Trial name
- NCT03180294
- Testing
- Bupropion 150 mg XL
- Where
- 362 sites in United States
- Volunteers
- 230 people
- Sponsor
- NRG Oncology
Vaginal Squamous Cell Carcinoma, Vulvar Squamous Cell Carcinoma
Sac-TMT in Vaginal and Vulvar Cancers
The ARCANA trial (LACOG 1724) is a single-arm, non-randomized, multi-center, parallel, two-cohort Phase II clinical study designed to evaluate the efficacy and safety of sacituzumab tirumotecan (sac-TMT, MK-2870) as a second-line…
- Trial name
- ARCANA (NCT07804966)
- Testing
- Sacituzumab Tirumotecan (sac-TMT)
- Where
- 12 sites in Brazil
- Volunteers
- 48 people
- Sponsor
- Latin American Cooperative Oncology Group
Gynaecological Cancers, Ovarian Cancer
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
The goal of the MYSSELF (Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers) study is to investigate which biological markers (i.e., (epi)genetic biomarkers) found in…
- Conditions
- Gynaecological Cancers, Ovarian Cancer, Endometrial Cancer, Vulvar Cancer
- Trial name
- MYSSELF (NCT07902375)
- Testing
- Colli-Pee 20 mL device with UCM, Evalyn Brush
- Where
- Belgium
- Volunteers
- 730 people
- Sponsor
- Universiteit Antwerpen
Gynecologic Neoplasm, Brachytherapy
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
The goal of this open label, randomized, controlled clinical trial is to assess the benefits of providing Reiki therapy to subjects receiving their first brachytherapy treatment for gynecological malignancies.
- Conditions
- Gynecologic Neoplasm, Brachytherapy, Therapeutic Touch, Endometrial Cancer
- Trial name
- Reiki-Brachy (NCT05979610)
- Testing
- Reiki therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Utah
Ovarian Carcinoma, Cervical Carcinoma
Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases.
Multicenter ambispective observational study (prospective/retrospective)
- Conditions
- Ovarian Carcinoma, Cervical Carcinoma, Endometrial Carcinoma, Vulvar Carcinoma
- Trial name
- NCT07267780
- Where
- 2 sites in Italy
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute, Naples
Ovarian Neoplasms, Endometrial Neoplasms
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Multicenter, randomized, open-label, phase II clinical study comparing Dostarlimab +/- Bevacizumab with standard chemotherapy in patients with gynecological clear cell carcinoma.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Vulvar Cancer
- Trial name
- DOVE (NCT06023862)
- Testing
- Dostarlimab, Bevacizumab, Doxorubicin
- Where
- 27 sites in Australia, Hong Kong and 5 more
- Volunteers
- 198 people
- Sponsor
- Yonsei University
Ovarian Cancer, Endometrial Cancer
ASk Questions in GYnecologic Oncology (ASQ-GYO)
The goal of this clinical trial is to determine the effectiveness of the ASk Questions in GYnecologic Oncology question prompt list (ASQ-GYO QPL) at improving patient self-efficacy, distress, physician trust, and knowledge…
- Conditions
- Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Vulvar Cancer
- Trial name
- ASQ-GYO (NCT06339827)
- Testing
- Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Ira Winer
Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer
Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva
This is an open-label, single arm, phase 2 study designed to evaluate the efficacy of tisotumab vedotin in participants with recurrent or metastatic squamous cell carcinoma of the vulva by estimating the objective response rate.
- Conditions
- Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer, Squamous Cell Carcinoma Vulva
- Trial name
- NCT07672782
- Testing
- Tisotumab Vedotin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- GOG Foundation
Cervical Cancers, Vulvar Cancer
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
This study will evaluate the immunogenicity and tolerability of V503 (a multivalent human papillomavirus [HPV] L1 virus-like particle [VLP] vaccine) in preadolescent and adolescent participants between 9 and 15 years old and…
- Conditions
- Cervical Cancers, Vulvar Cancer, Vaginal Cancer, Genital Lesions
- Trial name
- NCT00943722
- Testing
- V503
- Volunteers
- 3,074 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced, Squamous Cell Carcinoma of the Vulva
Treatment of Locally Advanced VULvar CArcinoma in a Neoadjuvant Setting With Carboplatin and Paclitaxel Chemotherapy (VULCANize)
Vulvar cancer is a rare malignancy. Surgery is the treatment of choice, but frequently causes invalidating and chronic postoperative morbidity, especially in patients with high stage disease.
- Trial name
- VULCANize (NCT04192253)
- Testing
- Paclitaxel and Carboplatin
- Where
- Netherlands
- Volunteers
- 51 people
- Sponsor
- The Netherlands Cancer Institute
Cervical Cancer, Vulvar Cancer
Survey on Lymphedema After Sentinel Lymph Node Biopsy in People With Cervical or Vulvar Cancer
The purpose of this study is to collect information that may identify people who are at risk of developing lower extremity lymphedema (LEL) after sentinel lymph node biopsy (SLN) during surgery for early-stage vulvar or cervical…
- Trial name
- NCT05255393
- Testing
- Questionnaires
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma, Breast Carcinoma
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma
- Trial name
- DUET-2 (NCT03517488)
- Testing
- XmAb20717
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Xencor, Inc.
Gastric Cancer, Pancreatic Cancer
Chemoradiation-Induced Nausea and Emesis: Quality of Life
The primary objectives of this study are: 1. To assess the preferences of cancer patients scheduled to receive chemoradiation and caregiver controls for side-effects of chemoradiation. 1.
- Conditions
- Gastric Cancer, Pancreatic Cancer, Cervical Cancer, Vulvar Cancer
- Trial name
- NCT00394602
- Testing
- Interview, Questionnaire
- Where
- United States
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Radio/Chemotherapy in Node Positive Advanced Vulvar Cancer
Chemo- and Radiotherapy in Epithelial Vulvar Cancer
This retrospective, multicenter study is designed to collect tumor characteristics as well as treatment data from patients diagnosed with primary or recurrent squamous cell cancer of the vulva with emphasis on indication and…
- Trial name
- CARE (NCT01304667)
- Where
- Germany
- Volunteers
- 1,618 people
- Sponsor
- AGO Study Group
Cervical Cancer, Vulvar Cancer
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
The purpose of this study is to evaluate vaccine immunogenicity and how well the body tolerates V504 when given with Gardasil.
- Conditions
- Cervical Cancer, Vulvar Cancer, Vaginal Cancer, Genital Warts
- Trial name
- NCT00551187
- Testing
- V504, Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Cancers, Vulvar Cancers
A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)
This study will evaluate whether V503 (9vHPV vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with GARDASIL™.
- Conditions
- Cervical Cancers, Vulvar Cancers, Vaginal Cancers, Genital Warts
- Trial name
- NCT01047345
- Testing
- V503
- Volunteers
- 924 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Inoperable Vulva Carcinoma
Electrochemotherapy for the Inoperable Vulva Carcinoma
Electrochemotherapy (ECT) with Bleomycin in non-operable advanced vulva carcinoma
- Trial name
- NCT03142061
- Testing
- Electrochemotherapy
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital Tuebingen